We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Simple Blood Sample to Diagnose TBI Severity Could Reduce Need for MRI Scan

By LabMedica International staff writers
Posted on 11 May 2022
Print article
Image: Researchers have identified blood biomarkers that indicate how serious a head trauma is (Photo courtesy of Pexels)
Image: Researchers have identified blood biomarkers that indicate how serious a head trauma is (Photo courtesy of Pexels)

Traumatic brain injury (TBI) is one of the most common neurological diseases worldwide affecting all ages and is commonly caused by a fall, road traffic accident or assault. TBI is divided into three categories ranging from mild to severe, although no reliable methods exist for ruling out acute brain injury. Researchers have now identified biomarkers in the blood that can indicate how serious a head trauma is, enabling a simple blood sample to diagnose TBI severity.

Researchers at Örebro University (Örebro, Sweden) who have been working on a non-surgical procedure to diagnose TBI severity used blood samples collected by EU project CENTER-TBI - the largest study of its kind. The EU project CENTER-TBI currently prospectively collects clinical data including records from 5,400 patients, files of imaging workup as well as blood samples from TBI patients from 60 sites of 18 countries. The overall objective is to apply metabolic profiling of serum in the CENTER-TBI cohort to study the utility of the existing as well as to identify novel biomarkers of TBI which are also predictive of patient outcomes.

Using metabolomics - a chemical analysis method to extract information about thousands of small molecules - the Örebro researchers have identified biomarkers that can be linked to TBI. With the help of these biomarkers, healthcare providers will not only be able to assess the severity of the injury but also predict the patient outcome. Healthcare providers will be able to categorize the injuries more clearly by simply taking a blood sample which is cost-effective, simpler and safer for the patient and eliminates the need for an MRI scan.

Related Links:
Örebro University 

Gold Supplier
Proficiency Assessment Software
CellaVision Proficiency Software
Automated R-AST Solution
Radian BC
Silver Supplier
3-Part Diff Hematology Analyzer
Abacus Junior 30
Auto Clinical Chemistry Analyzer
Mispa Clinia Plus

Print article


Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more


view channel
Image: The CS-2500 analyzer features pre-analytic sample checks and four detection methods simultaneously on a single platform – coagulation end-point, chromogenic kinetic analysis, turbidimetric immunoassay and automated platelet aggregation (Photo courtesy of Sysmex)

Microvascular/Endothelial Dysfunction Contributes to Post-COVID Syndrome Pathogenesis

Post-COVID syndrome (PCS) or Long-COVID is an increasingly recognized complication of acute SARS-CoV-2 infection, characterized by persistent fatigue, reduced exercise tolerance chest pain, shortness of... Read more


view channel
Image: Sales of lateral flow assays in clinical testing are expected to register a CAGR of 5% through 2032 (Photo courtesy of Pexels)

Global Lateral Flow Assays Market to Surpass USD 11.5 Billion by 2032 Due to Evolving Applications

The global lateral flow assays market was valued at USD 7.2 billion in 2021 and is projected to register a CAGR of 4.7% during 2022-2032 to surpass USD 11.7 billion by the end of 2032, driven by the growing... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.